Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.37 |
| ▸ | F10 | P00742 | 2/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21150756 | 0.86 | GPR119 (0.37) | ALDH1A1MAPTKMT2AF2F10 | |
| SCHEMBL24974367 | 0.85 | SMN1; SMN2 (0.40) | KMT2AMEN1KDM4ECYP1A2CYP2C9 | |
| SCHEMBL24974751 | 0.79 | ALDH1A1 (0.38) | ALDH1A1MAPTKMT2AF2F10 | |
| SCHEMBL24974651 | 0.76 | MT-CO2 (0.45) | ALDH1A1MAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL24974603 | 0.75 | NAMPT (0.43) | ALDH1A1MAPTKMT2AGRM4MEN1 | |
| SCHEMBL21150805 | 0.74 | YAP1 (0.46) | ALDH1A1MAPTKMT2AENPP2F2 | |
| SCHEMBL29590229 | 0.72 | GRM4 (0.48) | ALDH1A1MAPTKMT2AENPP2GRM4 | |
| SCHEMBL21150753 | 0.70 | GRM4 (0.46) | ALDH1A1KMT2AENPP2GRM4MEN1 | |
| SCHEMBL21150798 | 0.70 | GPR119 (0.57) | MAPTKDM4E | |
| SCHEMBL21150773 | 0.69 | ITGB3 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | ALDH1A1 1203/4885MAPT 4695/4885KMT2A 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.